Patients with elevated RPL22L1 expression in LUAD exhibit diminished immune and stromal elements in their tumor microenvironment, suggesting a potential association between heightened RPL22L1 expression and compromised immune status in LUAD patients. This evidence concerns the gene RPL22L1 and neoplasm.